ClinicalTrials.gg
RecruitingNCT07565805BIOCOREUpdated May 12, 2026

Bern Intracoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry

An observational study in Coronary Artery Disease (CAD), sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Insel Gruppe AG, University Hospital Bern · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
816
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern — 6 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Insel Gruppe AG, University Hospital Bern.

Planned enrollment
3rd of 11
816 · median 120
Started
2025
with 1 other
Observational
11 of 34
2 open now
Registered
34th of 34
by date

Among the 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2025, is one of 11 observational ones, and was the 34th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

6 of the 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern, or all of them as a file.
02

Study summary

Bern Intracoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry (BIOCORE) is a systematic institutional registry on patients undergoing paired CCTA and OCT for validation and development of advanced methods to determine coronary plaque morphology, lesion severity, PCI guidance, and it association with long-term clinical outcomes.

Read the detailed description

Intracoronary imaging represents the current gold standard for in-vivo assessment of plaque morphology and guidance of percutaneous coronary intervention (PCI). However, coronary computed tomography angiography (CCTA) plays an increasingly important role in the diagnostic pathway of CAD and represents a non-invasive procedure with wide availability, relatively low costs, and low radiation dose. Owing to its recent technical advances with the introduction of photon-counting CT with higher spatial resolution and diagnostic accuracy as compared to conventional CCTA, as well as recently developed artificial intelligence (AI)-guided analysis softwares, CCTA has the potential to provide more and more clinically essential information about coronary artery disease (CAD) with respect to plaque composition, lesion severity, need for intervention, and periprocedural planning that has traditionally been restricted to invasive coronary angiography and intracoronary imaging. Therefore, there is a timely need for systematic evaluation of advanced CCTA techniques against invasive gold standards. Furthermore, studies comparing CCTA to optical coherence tomography (OCT), the gold standard for plaque phenotyping, are scarce to date. Also, traditional treatment concepts of CAD that are based on obstructive stenosis and ischemia are currently challenged by an increasing body of evidence demonstrating the prognostic impact of plaque burden and composition independent of flow-limitation. Plaque burden and composition may emerge as the next treatment target in CAD. Therefore, the investigators established a systematic institutional registry on patients undergoing paired CCTA and OCT for validation and development of advanced methods to determine coronary plaque morphology, lesion severity, PCI guidance, and it association with long-term clinical outcomes.

03

Conditions studied

  • Coronary Artery Disease (CAD)

Keywords

  • Coronary artery disease (CAD)
  • Optical coherence tomography (OCT)
  • Coronary computed tomography angiography (CCTA)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing CCTA and invasive coronary angiography with OCT in native coronary vessels within 3 months

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years of age
  2. Written
  3. CCTA within 3 months from invasive coronary angiography and OCT
  4. At least one vessel with ≥50% diameter stenosis on CCTA
  5. OCT performed in native coronary arteries (i.e. pre-PCI or no PCI)

Exclusion criteria

Exclusion Criteria:

  1. CCTA performed more than 3 months from OCT
  2. Poor OCT quality
  3. Poor CCTA quality
  4. Coronary anomalies
  5. Prior PCI or CABG in the vessel imaged with OCT
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
816 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Patients undergoing paired CCTA and OCT

    Patients undergoing CCTA and invasive coronary angiography with OCT within 3 months

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy in plaque phenotyping CCTA vs. OCT

    Proportion of correctly classified plaques quantitative computed tomography (QCT) (low-attenuation, non-calcified, calcified plaques) against the gold standard OCT (lipid-rich, fibrous, fibro-calcific plaque)

    Time frame: Baseline

  2. PCI planning with CCTA vs. gold standard OCT

    Diagnostic accuracy of CCTA in identifying the need for PCI and agreement in stent sizing

    Time frame: Baseline

  3. Photon-counting vs. conventional CCTA

    Proportion of correctly classified plaques with photon-counting CCTA vs. conventional CCTA (low-attenuation, non-calcified, calcified plaques) against the gold standard OCT for plaque morphology (lipid-rich, fibrous, fibro-calcific plaque)

    Time frame: Baseline

Other outcomes

  1. Clinical outcomes throughout 1 and 5 years

    * All-cause death * Cardiovascular death * Myocardial infarction * Unstable angina pectoris * Clinically-driven coronary revascularization * Stent thrombosis * In-stent-restenosis

    Time frame: 1 and 5 years follow-up

07

Study locations

1 of 1 sites recruiting
  • Department of Cardiology, Bern University Hospital Inselspital
    Bern, 3010, Switzerland
    Recruiting
    • Sarah Bär, MD-PhD · Contactsarah.baer@insel.ch · +41316322111
    • Lorenz Räber, Prof. MD-PhD · Contactlorenz.raeber@insel.ch · +41316322111
    • Lorenz Räber, Prof. MD-PhD · Principal investigator
    • Sarah Bär, MD-PhD · Sub investigator
    • Christoph Gräni, Prof. MD-PhD · Sub investigator
08

References and documents

Publications

  • Raber L, Ueki Y, Otsuka T, Losdat S, Haner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns RJ, Ondracek AS, Radu Juul Jensen MD, Zanchin C, Stortecky S, Spirk D, Siontis GCM, Saleh L, Matter CM, Daemen J, Mach F, Heg D, Windecker S, Engstrom T, Lang IM, Koskinas KC; PACMAN-AMI collaborators. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022 May 10;327(18):1771-1781. doi: 10.1001/jama.2022.5218. PubMed 35368058 ↗
  • Bar S, Knuuti J, Saraste A, Nurmohamed NS, Jukema RA, Klen R, Bax JJ, Knaapen P, Danad I, Maaniitty T. Outcomes with revascularization vs. medical therapy according to plaque burden from coronary computed tomography angiography. Eur Heart J Cardiovasc Imaging. 2026 Feb 27;27(3):554-566. doi: 10.1093/ehjci/jeaf372. PubMed 41460775 ↗
  • Bar S, Knuuti J, Saraste A, Klen R, Kero T, Nabeta T, Bax JJ, Danad I, Nurmohamed NS, Jukema RA, Knaapen P, Maaniitty T. Derivation and validation of an artificial intelligence-based plaque burden safety cut-off for long-term acute coronary syndrome from coronary computed tomography angiography. Eur Heart J Cardiovasc Imaging. 2025 Jun 30;26(7):1163-1173. doi: 10.1093/ehjci/jeaf121. PubMed 40243706 ↗
  • Sandoval Y, Leipsic JA, Collet C, Ali ZA, Azzalini L, Barbato E, Cavalcante JL, Costa RA, Garcia-Garcia HM, Jones DA, Khoo JK, Maran A, Nieman K, Pinilla-Echeverri N, Seto AH, Shlofmitz E, Brilakis ES. Coronary Computed Tomography Angiography to Guide Percutaneous Coronary Intervention: Expert Opinion from a SCAI/SCCT Roundtable. J Soc Cardiovasc Angiogr Interv. 2025 May 1;4(6):103664. doi: 10.1016/j.jscai.2025.103664. eCollection 2025 Jun. PubMed 40630246 ↗
  • Williams MC, Kwiecinski J, Doris M, McElhinney P, D'Souza MS, Cadet S, Adamson PD, Moss AJ, Alam S, Hunter A, Shah ASV, Mills NL, Pawade T, Wang C, Weir McCall J, Bonnici-Mallia M, Murrills C, Roditi G, van Beek EJR, Shaw LJ, Nicol ED, Berman DS, Slomka PJ, Newby DE, Dweck MR, Dey D. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Circulation. 2020 May 5;141(18):1452-1462. doi: 10.1161/CIRCULATIONAHA.119.044720. Epub 2020 Mar 16. PubMed 32174130 ↗
  • Nieman K, Garcia-Garcia HM, Hideo-Kajita A, Collet C, Dey D, Pugliese F, Weissman G, Tijssen JGP, Leipsic J, Opolski MP, Ferencik M, Lu MT, Williams MC, Bruining N, Blanco PJ, Maurovich-Horvat P, Achenbach S. Standards for quantitative assessments by coronary computed tomography angiography (CCTA): An expert consensus document of the society of cardiovascular computed tomography (SCCT). J Cardiovasc Comput Tomogr. 2024 Sep-Oct;18(5):429-443. doi: 10.1016/j.jcct.2024.05.232. Epub 2024 Jun 6. PubMed 38849237 ↗

Individual participant data

Plan to share: No — Data will be shared upon reasonable request from the principal investigator.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2028, 38 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 38 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 4, 2026
StartActual
Oct 17, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2033
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07565805
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Oct 17, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2033 (estimated)
Last update
May 12, 2026

Study contacts

Sarah Bär, MD, PhD
Contact
sarah.baer@insel.ch
+41316322111
Räber Lorenz, Prof. MD PhD
Contact
lorenz.raeber@insel.ch
+41316322111
Lorenz Räber, Prof. MD-PhD
study chair · Department of Cardiology, Bern University Hospital Inselspital, Switzerland
Sarah Bär, MD-PhD
principal investigator · Department of Cardiology, Bern University Hospital Inselspital, Switzerland
Christoph Gräni, Prof. MD-PhD
principal investigator · Department of Cardiology, Bern University Hospital Inselspital, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion